The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease

N. Vakil, M (Brian) Fennerty, J. Freston, R. Hunt, R. Ganz, J. Barkin

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Approximately 5 million people in the United States suffer from peptic ulcer disease, making this an important clinical problem. In addition to the huge costs associated with treatment, peptic ulcer disease also results in losses to industry as a result of loss of productivity. Infection with Helicobacter pylori is now accepted as the cause of duodenal ulcer in the majority of patients. Eradication of this infection leads to healing of the ulcer and prevents disease recurrence. A number of treatment regimens have been described for the eradication of H. pylori, but there is uncertainty regarding the optimum regimen to be used. Economic analyses allow an assessment of the probable costs associated with existing and new treatment strategies. In an era of increasing cost awareness, the results of such analyses are becoming increasingly important determinants of management strategies for the treatment of H. pylori infection.

Original languageEnglish (US)
Pages (from-to)60S-64S
JournalAmerican Journal of Medicine
Volume100
Issue number5 A
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Duodenal Diseases
Helicobacter Infections
Duodenal Ulcer
Helicobacter pylori
Economics
Peptic Ulcer
Costs and Cost Analysis
Therapeutics
Infection
Ulcer
Uncertainty
Industry
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vakil, N., Fennerty, M. B., Freston, J., Hunt, R., Ganz, R., & Barkin, J. (1996). The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease. American Journal of Medicine, 100(5 A), 60S-64S.

The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease. / Vakil, N.; Fennerty, M (Brian); Freston, J.; Hunt, R.; Ganz, R.; Barkin, J.

In: American Journal of Medicine, Vol. 100, No. 5 A, 01.01.1996, p. 60S-64S.

Research output: Contribution to journalArticle

Vakil, N, Fennerty, MB, Freston, J, Hunt, R, Ganz, R & Barkin, J 1996, 'The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease', American Journal of Medicine, vol. 100, no. 5 A, pp. 60S-64S.
Vakil, N. ; Fennerty, M (Brian) ; Freston, J. ; Hunt, R. ; Ganz, R. ; Barkin, J. / The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease. In: American Journal of Medicine. 1996 ; Vol. 100, No. 5 A. pp. 60S-64S.
@article{6268a254bbf54208b5eb5372bb13aa72,
title = "The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease",
abstract = "Approximately 5 million people in the United States suffer from peptic ulcer disease, making this an important clinical problem. In addition to the huge costs associated with treatment, peptic ulcer disease also results in losses to industry as a result of loss of productivity. Infection with Helicobacter pylori is now accepted as the cause of duodenal ulcer in the majority of patients. Eradication of this infection leads to healing of the ulcer and prevents disease recurrence. A number of treatment regimens have been described for the eradication of H. pylori, but there is uncertainty regarding the optimum regimen to be used. Economic analyses allow an assessment of the probable costs associated with existing and new treatment strategies. In an era of increasing cost awareness, the results of such analyses are becoming increasingly important determinants of management strategies for the treatment of H. pylori infection.",
author = "N. Vakil and Fennerty, {M (Brian)} and J. Freston and R. Hunt and R. Ganz and J. Barkin",
year = "1996",
month = "1",
day = "1",
language = "English (US)",
volume = "100",
pages = "60S--64S",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "5 A",

}

TY - JOUR

T1 - The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease

AU - Vakil, N.

AU - Fennerty, M (Brian)

AU - Freston, J.

AU - Hunt, R.

AU - Ganz, R.

AU - Barkin, J.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Approximately 5 million people in the United States suffer from peptic ulcer disease, making this an important clinical problem. In addition to the huge costs associated with treatment, peptic ulcer disease also results in losses to industry as a result of loss of productivity. Infection with Helicobacter pylori is now accepted as the cause of duodenal ulcer in the majority of patients. Eradication of this infection leads to healing of the ulcer and prevents disease recurrence. A number of treatment regimens have been described for the eradication of H. pylori, but there is uncertainty regarding the optimum regimen to be used. Economic analyses allow an assessment of the probable costs associated with existing and new treatment strategies. In an era of increasing cost awareness, the results of such analyses are becoming increasingly important determinants of management strategies for the treatment of H. pylori infection.

AB - Approximately 5 million people in the United States suffer from peptic ulcer disease, making this an important clinical problem. In addition to the huge costs associated with treatment, peptic ulcer disease also results in losses to industry as a result of loss of productivity. Infection with Helicobacter pylori is now accepted as the cause of duodenal ulcer in the majority of patients. Eradication of this infection leads to healing of the ulcer and prevents disease recurrence. A number of treatment regimens have been described for the eradication of H. pylori, but there is uncertainty regarding the optimum regimen to be used. Economic analyses allow an assessment of the probable costs associated with existing and new treatment strategies. In an era of increasing cost awareness, the results of such analyses are becoming increasingly important determinants of management strategies for the treatment of H. pylori infection.

UR - http://www.scopus.com/inward/record.url?scp=85048352842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048352842&partnerID=8YFLogxK

M3 - Article

C2 - 8644784

AN - SCOPUS:85048352842

VL - 100

SP - 60S-64S

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 5 A

ER -